The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine

Leukemia

Volumn 25, Issue 3, 2011, Pages 411-419

  Walsby, E ^a   Lazenby, M ^a   Pepper, C ^a   Burnett, A K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

acute myeloid leukemia; cyclin dependent kinases; therapy

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; LIPOCORTIN 5; MESSENGER RNA; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PROTEIN BCL 2; PROTEIN MCL 1; RNA POLYMERASE II; SERINE; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; AGED; APOPTOSIS; ARTICLE; BLAST CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LD 50; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; STAINING;

EID: 79952443627     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.290     Document Type: Article

References (43)

1. Kiyoi H, Naoe T. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. Int J Hematol 2006; 83: 301-308. . (Pubitemid 43807573)
2. Sanz M, Burnett A, Lo-Coco F, Lowenberg B. FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr Opin Oncol 2009; 21: 594-600. .
3. Mesters RM, Padro T, Bieker R, Steins M, Kreuter M, Goner M et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001; 98: 241-243. .
4. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003; 102: 795-801. . (Pubitemid 36917765)
5. Mountzios G, Terpos E, Dimopoulos MA. Aurora kinases as targets for cancer therapy. Cancer Treat Rev 2008; 34: 175-182. . (Pubitemid 351372885)
6. Wallenfang MR, Seydoux G. cdk-7 Is required for mRNA transcription and cell cycle progression in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA 2002; 99: 5527-5532. . (Pubitemid 34411582)
7. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770-1783. . (Pubitemid 46628473)
8. Scrace SF, Kierstan P, Borgognoni J, Wang LZ, Denny S, Wayne J et al. Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked. Cell Cycle 2008; 7: 3898-3907. .
9. Maude SL, Enders GH. Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. Cancer Res 2005; 65: 780-786. . (Pubitemid 40216435)
10. Cai D, Latham Jr VM, Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006; 66: 9270-9280. . (Pubitemid 44521149)
11. Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P et al. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 2003; 63: 1822-1833. . (Pubitemid 36460844)
12. Grant S, Roberts JD. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist Updat 2003; 6: 15-26. . (Pubitemid 36396111)
13. Lolli G, Johnson LN. CAK-Cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs? Cell Cycle 2005; 4: 572-577. . (Pubitemid 41359784)
14. Larochelle S, Pandur J, Fisher RP, Salz HK, Suter B. Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity. Genes Dev 1998; 12: 370-381. . (Pubitemid 28084265)
15. Shuttleworth J. The regulation and functions of cdk7. Prog Cell Cycle Res 1995; 1: 229-240. .
16. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 2009; 113: 4637-4645. .
17. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009; 16: 36-43. .
18. Ali MA, Choy H, Habib AA, Saha D. SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia 2007; 9: 370-381. . (Pubitemid 46799980)
19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55. .
20. White JC, Rathmell JP, Capizzi RL. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. J Clin Invest 1987; 79: 380-387. . (Pubitemid 17009669)
21. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005; 106: 2513-2519. . (Pubitemid 41510827)
22. Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P et al. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 2003; 63: 1822-1833. . (Pubitemid 36460844)
23. Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, Gimenez MS et al. Mechanism and functional role of XIAP and Mcl-1 downregulation in flavopiridol/vorinostat antileukemic interactions. Mol Cancer Ther 2007; 6: 692-702. . (Pubitemid 46332470)
24. Maung ZT, MacLean FR, Reid MM, Pearson AD, Proctor SJ, Hamilton PJ et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol 1994; 88: 105-109. . (Pubitemid 24293860)
25. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998; 9: 159-165. . (Pubitemid 28123617)
26. Notarbartolo M, Cervello M, Dusonchet L, Cusimano A, D'Alessandro N. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett 2002; 180: 91-101. . (Pubitemid 34242969)
27. Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT et al. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 2008; 111: 3742-3750. .
28. Lubbert M, Muller-Tidow C, Hofmann WK, Koeffler HP. Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy. J Cell Biochem 2008; 104: 2059-2070. .
29. Estey E. New drugs in acute myeloid leukemia. Semin Oncol 2008; 35: 439-448. .
30. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008; 22: 915-931. . (Pubitemid 351709343)
31. Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des 2000; 6: 379-392. . (Pubitemid 30396403)
32. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclindependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005; 106: 1042-1047. . (Pubitemid 41076452)
33. Tirado OM, Mateo-Lozano S, Notario V. Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Cancer Res 2005; 65: 9320-9327. . (Pubitemid 41507999)
34. Hui AB, Yue S, Shi W, Alajez NM, Ito E, Green SR et al. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Clin Cancer Res 2009; 15: 3716-3724. .
35. Drexler HG, Quentmeier H, MacLeod R. Cell line models of leukemia. Drug Discov Today: Disease Models 2005; 2: 51-56. . (Pubitemid 40932059)
36. Moon JH, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW et al. BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. Leuk Res 2010; 34: 166-172. .
37. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 1999; 5: 1758-1766. . (Pubitemid 29334457)
38. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803. . (Pubitemid 30305074)
39. Konopleva M, Tari AM, Estrov Z, Harris D, Xie Z, Zhao S et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood 2000; 95: 3929-3938. . (Pubitemid 30412870)
40. Ibrado AM, Huang Y, Fang G, Liu L, Bhalla K. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 1996; 56: 4743-4748. . (Pubitemid 26338079)
41. Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA et al. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 2004; 47: 1719-1728. . (Pubitemid 38380915)
42. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399-404. . (Pubitemid 46105932)
43. Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 2008; 26: 59-65.